首页 > 最新文献

Deutsche medizinische Wochenschrift (1946)最新文献

英文 中文
[Haematology and Oncology - A look back at 150 years]. [血液学和肿瘤学-回顾150年]。
Pub Date : 2024-12-01 Epub Date: 2024-12-04 DOI: 10.1055/a-2298-0609
Wolfgang Hiddemann

The success story of haematology and oncology extends from Virchow's concept of "cellular pathology" to the possibilities of personalized cancer therapy, which molecular oncology offers today. This article highlights the beginnings and developments of chemotherapy, immunotherapy, as well as molecular oncology and psycho-oncology over the past 150 years.

血液学和肿瘤学的成功故事从Virchow的“细胞病理学”概念延伸到今天分子肿瘤学提供的个性化癌症治疗的可能性。本文重点介绍了过去150年来化疗、免疫治疗以及分子肿瘤学和心理肿瘤学的起源和发展。
{"title":"[Haematology and Oncology - A look back at 150 years].","authors":"Wolfgang Hiddemann","doi":"10.1055/a-2298-0609","DOIUrl":"10.1055/a-2298-0609","url":null,"abstract":"<p><p>The success story of haematology and oncology extends from Virchow's concept of \"cellular pathology\" to the possibilities of personalized cancer therapy, which molecular oncology offers today. This article highlights the beginnings and developments of chemotherapy, immunotherapy, as well as molecular oncology and psycho-oncology over the past 150 years.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 24-25","pages":"1500-1506"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chronic constipation]. [慢性便秘]
Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1055/a-2194-3285
Viola Andresen, Peter Layer

Chronic constipation is one of the most common health disorders in all of medicine. Its extent ranges from mild discomfort, which is usually easy to improve, to severe functional limitations that may significantly reduce quality of life and may be refractory to various treatment approaches. Our understanding of the pathomechanism has grown considerably in recent years and has also led to important new therapeutic developments. The resulting treatment options and recommendations are presented in the current update of the S2k constipation guideline in an evidence-based and practical manner. The respective significance of traditional and recent drug developments is classified and categorized in modern "step-up" treatment strategies. In particular, numerous important aspects of everyday practice are addressed, such as questions on long-term treatment and therapeutic options in specific constellations (adequate treatment of constipation in older people, constipation during pregnancy, and drug-induced [especially opioid-induced]constipation).The most important new developments (i.e. new therapeutic approaches, but also re-evaluations of "traditional" laxatives and the importance of careful diagnostics in therapy-refractory patients) are summarized in this article.

慢性便秘是医学界最常见的健康疾病之一。其程度从通常容易改善的轻微不适,到严重的功能限制,可能会大大降低生活质量,并可能对各种治疗方法产生耐药性。近年来,我们对其病理机制的认识有了很大的提高,同时也带来了重要的治疗新进展。本期更新的 S2k 便秘指南以循证和实用的方式介绍了由此产生的治疗方案和建议。在现代 "阶梯式 "治疗策略中,对传统药物和最新药物发展的各自意义进行了分类和归纳。本文总结了最重要的新进展(即新的治疗方法,也包括对 "传统 "泻药的重新评估,以及对难治性患者进行仔细诊断的重要性)。
{"title":"[Chronic constipation].","authors":"Viola Andresen, Peter Layer","doi":"10.1055/a-2194-3285","DOIUrl":"10.1055/a-2194-3285","url":null,"abstract":"<p><p>Chronic constipation is one of the most common health disorders in all of medicine. Its extent ranges from mild discomfort, which is usually easy to improve, to severe functional limitations that may significantly reduce quality of life and may be refractory to various treatment approaches. Our understanding of the pathomechanism has grown considerably in recent years and has also led to important new therapeutic developments. The resulting treatment options and recommendations are presented in the current update of the S2k constipation guideline in an evidence-based and practical manner. The respective significance of traditional and recent drug developments is classified and categorized in modern \"step-up\" treatment strategies. In particular, numerous important aspects of everyday practice are addressed, such as questions on long-term treatment and therapeutic options in specific constellations (adequate treatment of constipation in older people, constipation during pregnancy, and drug-induced [especially opioid-induced]constipation).The most important new developments (i.e. new therapeutic approaches, but also re-evaluations of \"traditional\" laxatives and the importance of careful diagnostics in therapy-refractory patients) are summarized in this article.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1324-1328"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical reasoning, the art of medicine and artificial intelligence]. [临床推理、医学艺术与人工智能]。
Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1055/a-2201-5412
Stefano Bassetti, Martin C Hirsch, Edouard Battegay

"Clinical reasoning" refers to all the thought processes that physicians use to make a diagnosis and determine a treatment and care plan. Artificial intelligence (AI) will enhance, improve, and accelerate human clinical diagnostic thinking, but it is unlikely to replace it. Its application in medicine has the potential to drastically reduce medical diagnostic errors and give doctors more time to care for their patients. Here, we provide an overview of some of the key elements of clinical diagnostic reasoning and the potential impacts of AI on clinical reasoning.

"临床推理 "是指医生用来做出诊断、确定治疗和护理计划的所有思维过程。人工智能(AI)将增强、改善和加速人类的临床诊断思维,但不可能取代人类的临床诊断思维。人工智能在医学中的应用有可能大幅减少医疗诊断错误,让医生有更多时间照顾病人。在此,我们将概述临床诊断推理的一些关键要素以及人工智能对临床推理的潜在影响。
{"title":"[Clinical reasoning, the art of medicine and artificial intelligence].","authors":"Stefano Bassetti, Martin C Hirsch, Edouard Battegay","doi":"10.1055/a-2201-5412","DOIUrl":"10.1055/a-2201-5412","url":null,"abstract":"<p><p>\"Clinical reasoning\" refers to all the thought processes that physicians use to make a diagnosis and determine a treatment and care plan. Artificial intelligence (AI) will enhance, improve, and accelerate human clinical diagnostic thinking, but it is unlikely to replace it. Its application in medicine has the potential to drastically reduce medical diagnostic errors and give doctors more time to care for their patients. Here, we provide an overview of some of the key elements of clinical diagnostic reasoning and the potential impacts of AI on clinical reasoning.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1401-1410"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Handover of intensive care patients]. [重症监护病人的交接]
Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1055/a-2136-4088
Julia Banken, Eyleen Reifarth, Stephan Braune

An effective patient handover is a core element of high-quality patient care. Communication during patient handover in the intensive care unit is particularly challenging due to the clinical complexity and rapid changes in patient trajectories, complex interdisciplinary and interprofessional interfaces, linguistic barriers, situational and structural disruptive factors, personnel stress factors as well as the communication and error culture of the teams. In addition to avoiding disruptive factors and creating optimal communication conditions and human resources, the use of standardized and structured handovers with the help of protocols and checklists, as recommended in the literature, plays a decisive role as part of a bundle of measures for effective and safe patient care.

有效的患者交接是高质量患者护理的核心要素。由于临床复杂性和病人轨迹的快速变化、复杂的跨学科和跨专业界面、语言障碍、情景和结构性干扰因素、人员压力因素以及团队的沟通和错误文化,在重症监护病房进行病人交接时的沟通尤其具有挑战性。除了避免干扰因素、创造最佳沟通条件和人力资源外,文献中推荐的借助协议和核对表使用标准化和结构化交接班,作为有效和安全的患者护理措施的一部分,发挥着决定性的作用。
{"title":"[Handover of intensive care patients].","authors":"Julia Banken, Eyleen Reifarth, Stephan Braune","doi":"10.1055/a-2136-4088","DOIUrl":"https://doi.org/10.1055/a-2136-4088","url":null,"abstract":"<p><p>An effective patient handover is a core element of high-quality patient care. Communication during patient handover in the intensive care unit is particularly challenging due to the clinical complexity and rapid changes in patient trajectories, complex interdisciplinary and interprofessional interfaces, linguistic barriers, situational and structural disruptive factors, personnel stress factors as well as the communication and error culture of the teams. In addition to avoiding disruptive factors and creating optimal communication conditions and human resources, the use of standardized and structured handovers with the help of protocols and checklists, as recommended in the literature, plays a decisive role as part of a bundle of measures for effective and safe patient care.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1348-1355"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Genetics in nephrology - any news?] [肾脏病学中的遗传学--有新消息吗?]
Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1055/a-2198-0363
Malte P Bartram, Bodo B Beck, Roman-Ulrich Müller

While genetic kidney diseases were long regarded as a rare cause of kidney failure, it has been shown in recent years that they account for a relevant proportion of cases. In cohorts of kidney transplant recipients, a monogenic cause is found in up to 30% of cases. Identifying the genetic cause of kidney disease has become much easier thanks to technological advances in DNA sequencing. The focus has now shifted to understanding the significance of the findings and identifying diagnostic gaps. It is still not possible to clarify all CKD cases of unclear aetiology. Besides very effective generic treatments for monogenic kidney disease (e.g., ACE-inhibitor use in Alport Syndrome), increasing knowledge of the pathophysiology of genetic kidney diseases has led to a growing number of targeted therapies. These include the treatment of ADPKD with Tolvaptan, which has now been in use for 10 years. Recently, exciting, and completely new approaches have been added, such as the first siRNA therapies in nephrology for primary hyperoxaluria type 1, the targeted treatment of hyperphagia in Bardet-Biedl syndrome, the therapy of APOL1-associated kidney disease or the use of the HIF-2 antagonist Belzutifan for renal cell carcinoma associated with Von-Hippel-Lindau syndrome. The new possibilities in the treatment of patients with genetic kidney diseases have also clearly revealed deficits in current patient care. Centers of excellence with extensive experience in this area therefore play an important role in improving care. This also applies to the further training of colleagues in the field. In Germany, the National Action Alliance for People with Rare Diseases (NAMSE) and the nationwide establishment of - to date - 36 centers for rare diseases play an important role in this regard.

长期以来,遗传性肾病被认为是肾衰竭的罕见病因,但近年来的研究表明,遗传性肾病在肾衰竭病例中占有相当大的比例。在接受肾移植的人群中,发现单基因病因的病例高达 30%。由于 DNA 测序技术的进步,确定肾病的遗传原因变得更加容易。现在的重点已转移到了解研究结果的意义和确定诊断差距上。目前仍无法澄清所有病因不明的慢性肾脏病病例。除了针对单基因肾病的非常有效的普通治疗方法(如在阿尔波特综合征中使用 ACE 抑制剂)外,对遗传性肾病病理生理学的进一步了解促使越来越多的靶向疗法应运而生。其中包括使用托伐普坦(Tolvaptan)治疗 ADPKD,该疗法现已使用了 10 年。最近,又出现了一些令人兴奋的全新方法,如肾脏病学中首个用于治疗原发性高草酸尿症 1 型的 siRNA 疗法、针对 Bardet-Biedl 综合征多食症的靶向治疗、APOL1 相关肾病的治疗或使用 HIF-2 拮抗剂 Belzutifan 治疗 Von-Hippel-Lindau 综合征相关肾细胞癌。治疗遗传性肾病患者的新可能性也清楚地揭示了目前患者护理中的不足之处。因此,在这一领域拥有丰富经验的卓越中心在改善护理方面发挥着重要作用。这也适用于对该领域同行的进一步培训。在德国,罕见病患者国家行动联盟(NAMSE)以及迄今为止在全国范围内建立的 36 个罕见病中心在这方面发挥了重要作用。
{"title":"[Genetics in nephrology - any news?]","authors":"Malte P Bartram, Bodo B Beck, Roman-Ulrich Müller","doi":"10.1055/a-2198-0363","DOIUrl":"https://doi.org/10.1055/a-2198-0363","url":null,"abstract":"<p><p>While genetic kidney diseases were long regarded as a rare cause of kidney failure, it has been shown in recent years that they account for a relevant proportion of cases. In cohorts of kidney transplant recipients, a monogenic cause is found in up to 30% of cases. Identifying the genetic cause of kidney disease has become much easier thanks to technological advances in DNA sequencing. The focus has now shifted to understanding the significance of the findings and identifying diagnostic gaps. It is still not possible to clarify all CKD cases of unclear aetiology. Besides very effective generic treatments for monogenic kidney disease (e.g., ACE-inhibitor use in Alport Syndrome), increasing knowledge of the pathophysiology of genetic kidney diseases has led to a growing number of targeted therapies. These include the treatment of ADPKD with Tolvaptan, which has now been in use for 10 years. Recently, exciting, and completely new approaches have been added, such as the first siRNA therapies in nephrology for primary hyperoxaluria type 1, the targeted treatment of hyperphagia in Bardet-Biedl syndrome, the therapy of APOL1-associated kidney disease or the use of the HIF-2 antagonist Belzutifan for renal cell carcinoma associated with Von-Hippel-Lindau syndrome. The new possibilities in the treatment of patients with genetic kidney diseases have also clearly revealed deficits in current patient care. Centers of excellence with extensive experience in this area therefore play an important role in improving care. This also applies to the further training of colleagues in the field. In Germany, the National Action Alliance for People with Rare Diseases (NAMSE) and the nationwide establishment of - to date - 36 centers for rare diseases play an important role in this regard.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1361-1366"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Outpatient exercise training for chronic lung disease - for whom, how and why?] [慢性肺病的门诊运动训练--为谁、如何、为什么?]
Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1055/a-2165-5788
Rainer Gloeckl, Inga Jarosch, Andreas Rembert Koczulla

There is a legal entitlement to participate in outpatient exercise groups in accordance with the German Social Code (Book IX) which regulates and facilitates prescriptions for patients with chronic respiratory diseases. A medical examination with specific inclusion and exclusion criteria prior to admission to an exercise group ensures safe participation.Traditional outpatient exercise groups are conducted in face-to-face groups for 60 to 90 minutes, once a week, with structured warm-up, main and cool-down phases. In addition, since the coronavirus pandemic, the introduction of online exercise groups via videoconferencing has enabled flexible participation (even without a prescription). To date, more than 11,000 German patients have participated in online exercise groups since 2021.Scientific evidence confirms the significant benefits of regular exercise, such as improved physical performance and reduced breathlessness. The psychosocial benefits and the promotion of self-efficacy are additionally supported by the supervision of a specialized trainer. Regular exercise (e.g. in outpatient exercise groups) is an inexpensive and very effective form of therapy to improve the quality of life of people with chronic respiratory diseases.

根据《德国社会法典》(第九部)的规定,参加门诊锻炼小组是一项合法权利,该法典对慢性呼吸道疾病患者的处方做出了规定并为处方提供了便利。传统的门诊锻炼小组以面对面的方式进行,每周一次,每次 60 至 90 分钟,有组织地安排热身、主要锻炼和冷却阶段。此外,自冠状病毒大流行以来,通过视频会议引入的在线锻炼小组使人们能够灵活参与(甚至无需处方)。自 2021 年以来,迄今已有 11,000 多名德国患者参加了在线锻炼小组。科学证据证实,定期锻炼具有显著的益处,如提高身体机能和减少呼吸困难。此外,在专业培训人员的指导下,还能提高心理社会效益和自我效能。定期锻炼(如参加门诊锻炼小组)是改善慢性呼吸系统疾病患者生活质量的一种廉价且非常有效的治疗方式。
{"title":"[Outpatient exercise training for chronic lung disease - for whom, how and why?]","authors":"Rainer Gloeckl, Inga Jarosch, Andreas Rembert Koczulla","doi":"10.1055/a-2165-5788","DOIUrl":"https://doi.org/10.1055/a-2165-5788","url":null,"abstract":"<p><p>There is a legal entitlement to participate in outpatient exercise groups in accordance with the German Social Code (Book IX) which regulates and facilitates prescriptions for patients with chronic respiratory diseases. A medical examination with specific inclusion and exclusion criteria prior to admission to an exercise group ensures safe participation.Traditional outpatient exercise groups are conducted in face-to-face groups for 60 to 90 minutes, once a week, with structured warm-up, main and cool-down phases. In addition, since the coronavirus pandemic, the introduction of online exercise groups via videoconferencing has enabled flexible participation (even without a prescription). To date, more than 11,000 German patients have participated in online exercise groups since 2021.Scientific evidence confirms the significant benefits of regular exercise, such as improved physical performance and reduced breathlessness. The psychosocial benefits and the promotion of self-efficacy are additionally supported by the supervision of a specialized trainer. Regular exercise (e.g. in outpatient exercise groups) is an inexpensive and very effective form of therapy to improve the quality of life of people with chronic respiratory diseases.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1367-1371"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Human versus Artificial Intelligence: who makes the decision?] [人类与人工智能:谁做决定?]
Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1055/a-2179-9964
Edouard Battegay
{"title":"[Human versus Artificial Intelligence: who makes the decision?]","authors":"Edouard Battegay","doi":"10.1055/a-2179-9964","DOIUrl":"https://doi.org/10.1055/a-2179-9964","url":null,"abstract":"","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1379-1380"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Renal infarction by cannabis consumption]. [吸食大麻导致肾梗塞]。
Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1055/a-2406-6891
Oliver Kolks, Stefan Stahlhoff, Michael Lichtenberg

Introduction:  Renal infarction is a rare cause for an acute renal failure. At the time being, there is no sufficient correlation to the consumption of cannabis described.

Case history:  A 40-year-old male patient presented to our emergency room because of pain in the right renal bed.

Examination and findings:  The duplex ultrasound showed no ectasia, but the computed tomography confirmed a renal infraction on the right side. The further diagnostics gave no indication of a classical pathogenesis, but there was a constant consumption of cannabis documented.

Therapy and course:  We decided for a conservative treatment with analgesia, diagnostic laboratory controls and anticoagulants because of the prolonged process. The complaints decreased.

Discussion:  The correlation between thrombo-embolic events and the consumption of cannabis has to be more explored because of its recent legalization in Germany. It should be considered as a cardiovascular risk factor. Until today there are no recommendations for the anticoagulants.

简介肾梗塞是导致急性肾功能衰竭的罕见原因。目前,尚未发现与吸食大麻有充分的关联:一名 40 岁的男性患者因右肾床疼痛而来到我们的急诊室:检查和发现:双相超声波检查未发现异位,但计算机断层扫描证实右侧肾脏梗塞。进一步诊断未发现典型的发病机制,但有持续吸食大麻的记录:治疗和病程:由于病程较长,我们决定采取保守治疗,包括镇痛、实验室诊断控制和抗凝剂。讨论讨论:由于大麻最近在德国合法化,血栓栓塞事件与大麻消费之间的相关性有待进一步探讨。大麻应被视为心血管风险因素。到目前为止,还没有关于抗凝剂的建议。
{"title":"[Renal infarction by cannabis consumption].","authors":"Oliver Kolks, Stefan Stahlhoff, Michael Lichtenberg","doi":"10.1055/a-2406-6891","DOIUrl":"https://doi.org/10.1055/a-2406-6891","url":null,"abstract":"<p><strong>Introduction: </strong> Renal infarction is a rare cause for an acute renal failure. At the time being, there is no sufficient correlation to the consumption of cannabis described.</p><p><strong>Case history: </strong> A 40-year-old male patient presented to our emergency room because of pain in the right renal bed.</p><p><strong>Examination and findings: </strong> The duplex ultrasound showed no ectasia, but the computed tomography confirmed a renal infraction on the right side. The further diagnostics gave no indication of a classical pathogenesis, but there was a constant consumption of cannabis documented.</p><p><strong>Therapy and course: </strong> We decided for a conservative treatment with analgesia, diagnostic laboratory controls and anticoagulants because of the prolonged process. The complaints decreased.</p><p><strong>Discussion: </strong> The correlation between thrombo-embolic events and the consumption of cannabis has to be more explored because of its recent legalization in Germany. It should be considered as a cardiovascular risk factor. Until today there are no recommendations for the anticoagulants.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1420-1422"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis]. [肺部疾病的疫苗接种--第二部分:疱疹病毒、RSV、肺炎球菌感染和百日咳]。
Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1055/a-2372-1157
Cathrin Kodde, Leif Erik Sander

Rsv (respiratory syncytial virus): RSV is a common cause of respiratory tract infections, posing a risk of severe disease, particularly for newborns and infants, as well as in older individuals with pre-existing conditions. Two safe and effective RSV vaccines were approved in 2023. These vaccines elicit protective antibodies and offer robust protection with no additional benefit from annual boosters. Both vaccines have been approved for individuals aged 60 years and older, while one of the vaccines has also been approved in pregnant women to elicit maternal immunity for passive protection of the unborn child. In Germany, RSV vaccination is currently recommended for all individuals aged 75 years and older, as well as people aged 60-74 years of age with severe underlying conditions. PNEUMOCOCCAL INFECTION: Streptococcus pneumoniae is a primary cause of community-acquired pneumonia (CAP). Since early 2022, a 20-valent conjugate vaccine (PCV20) is approved and recommended for people over 60 years of age and individuals over 18 years of age with risk factors. PCV20 replaces the 23-valent polysaccharide vaccine (PPV23) previously recommended for those over 60 years of age.

Pertussis: Although viewed primarily as a childhood disease, the majority of infections affect adults. Patients with chronic respiratory diseases are at a higher risk for severe clinical course of pertussis infection. It has therefore been recommended that all adults should get a pertussis booster with their next scheduled tetanus vaccination, given as a combination vaccine (Tdap). For risk groups (healthcare personnel, community facilities) a booster vaccination every 10 years is recommended.

Herpes zoster: Herpes Zoster (shingles) is caused by the varicella-zoster virus, and reactivations can lead to painful skin lesions and potential complications such as herpes zoster oticus, meningitis, or postherpetic neuralgia. People with chronic lung diseases such as COPD or asthma are at increased risk of herpes zoster-related complications. A recombinant adjuvanted inactivated vaccine was approved in 2018 and offers robust protection against herpes zoster and its complications. The vaccine is recommended for all people over 60 years of age and for certain risk groups over 50 years of age.

RSV(呼吸道合胞病毒):RSV 是呼吸道感染的常见病因,有导致严重疾病的风险,尤其是对新生儿和婴儿,以及患有原有疾病的老年人。2023 年,两种安全有效的 RSV 疫苗获得批准。这些疫苗可激发保护性抗体,并提供强有力的保护,每年接种一次不会带来额外的益处。这两种疫苗都已获批用于 60 岁及以上人群,其中一种疫苗还获批用于孕妇,以激发母体免疫力,为胎儿提供被动保护。在德国,目前建议所有 75 岁及以上的老人以及患有严重基础疾病的 60-74 岁老人接种 RSV 疫苗。肺炎球菌感染:肺炎链球菌是社区获得性肺炎(CAP)的主要病因。自 2022 年初起,20 价结合疫苗 (PCV20) 获得批准并被推荐用于 60 岁以上人群和 18 岁以上有风险因素的人群。PCV20 取代了之前推荐 60 岁以上人群接种的 23 价多糖疫苗(PPV23):虽然百日咳主要被视为儿童疾病,但大多数感染都会影响成年人。慢性呼吸道疾病患者感染百日咳后出现严重临床症状的风险更高。因此,建议所有成年人在下次接种破伤风疫苗时接种百日咳强化疫苗(百白破联合疫苗)。对于高危人群(医护人员、社区机构),建议每 10 年加强接种一次:带状疱疹(带状疱疹)是由水痘-带状疱疹病毒引起的,再次激活可导致疼痛的皮肤损伤和潜在的并发症,如耳部带状疱疹、脑膜炎或带状疱疹后遗神经痛。患有慢性阻塞性肺病或哮喘等慢性肺部疾病的人患带状疱疹相关并发症的风险会增加。重组佐剂灭活疫苗于 2018 年获得批准,可为带状疱疹及其并发症提供强有力的保护。建议 60 岁以上的所有人群和 50 岁以上的特定风险人群接种该疫苗。
{"title":"[Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis].","authors":"Cathrin Kodde, Leif Erik Sander","doi":"10.1055/a-2372-1157","DOIUrl":"https://doi.org/10.1055/a-2372-1157","url":null,"abstract":"<p><strong>Rsv (respiratory syncytial virus): </strong>RSV is a common cause of respiratory tract infections, posing a risk of severe disease, particularly for newborns and infants, as well as in older individuals with pre-existing conditions. Two safe and effective RSV vaccines were approved in 2023. These vaccines elicit protective antibodies and offer robust protection with no additional benefit from annual boosters. Both vaccines have been approved for individuals aged 60 years and older, while one of the vaccines has also been approved in pregnant women to elicit maternal immunity for passive protection of the unborn child. In Germany, RSV vaccination is currently recommended for all individuals aged 75 years and older, as well as people aged 60-74 years of age with severe underlying conditions. PNEUMOCOCCAL INFECTION: <i>Streptococcus pneumoniae</i> is a primary cause of community-acquired pneumonia (CAP). Since early 2022, a 20-valent conjugate vaccine (PCV20) is approved and recommended for people over 60 years of age and individuals over 18 years of age with risk factors. PCV20 replaces the 23-valent polysaccharide vaccine (PPV23) previously recommended for those over 60 years of age.</p><p><strong>Pertussis: </strong>Although viewed primarily as a childhood disease, the majority of infections affect adults. Patients with chronic respiratory diseases are at a higher risk for severe clinical course of pertussis infection. It has therefore been recommended that all adults should get a pertussis booster with their next scheduled tetanus vaccination, given as a combination vaccine (Tdap). For risk groups (healthcare personnel, community facilities) a booster vaccination every 10 years is recommended.</p><p><strong>Herpes zoster: </strong>Herpes Zoster (shingles) is caused by the varicella-zoster virus, and reactivations can lead to painful skin lesions and potential complications such as herpes zoster oticus, meningitis, or postherpetic neuralgia. People with chronic lung diseases such as COPD or asthma are at increased risk of herpes zoster-related complications. A recombinant adjuvanted inactivated vaccine was approved in 2018 and offers robust protection against herpes zoster and its complications. The vaccine is recommended for all people over 60 years of age and for certain risk groups over 50 years of age.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1372-1376"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Nutrition for patients on dialysis]. [透析患者的营养]。
Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1055/a-2199-8816
Martin K Kuhlmann, Susanne Fleig

Dietary recommendations for patients on dialysis are changing as our understanding of enteral microbiotal metabolism and bioavailability of nutrients from food improves.A diet low in phosphate and potassium is recommended for patients on hemodialysis. However, the absolute content does not reflect bioavailability: How much phosphate or potassium is taken up depends on food source (plant vs. animal) and to which grade it is processed. While both are nearly 100% bioavailable from industrially processed foods (additives such as dipotassium-phosphate and other salts), a much lower proportion is taken up from unprocessed plant foods high in fibre (ca. 20-40%). The DIET-HD study showed no significant association between dietary potassium and serum potassium in > 8 000 dialysis patients; and those with the highest low-processed, fresh plant-food consumption have the best survival. Dietary fibre improves colon transit time and thereby lessens symptoms of constipation. A diet low in sodium improves blood pressure and volume management in dialysis patients. The energy and protein requirements on dialysis are high: 25-35 kcal and 1-1,2 g protein per kg body weight per day (in relation to "ideal" body weight, if patient is overweight). Protein energy wasting is associated with higher stages of kidney disease, and malnutrition is associated with worse survival on dialysis. Nutritional status should be assessed on a regular basis using validated scores, and malnutrition should be addressed and treated.

随着我们对肠内微生物代谢和食物中营养物质生物利用率的认识不断提高,针对透析患者的饮食建议也在发生变化。然而,绝对含量并不能反映生物利用率:磷酸盐或钾的吸收量取决于食物来源(植物还是动物)以及食物的加工等级。工业加工食品(添加剂,如磷酸氢二钾和其他盐类)中的磷酸盐和钾的生物利用率几乎达到 100%,而未经加工的高纤维植物性食品中的磷酸盐和钾的生物利用率要低得多(约为 20-40%)。DIET-HD 研究显示,在超过 8000 名透析患者中,膳食钾与血清钾之间没有明显的关联;而那些食用低加工、新鲜植物性食物最多的患者生存率最高。膳食纤维可改善结肠转运时间,从而减轻便秘症状。低钠饮食可改善透析患者的血压和血容量管理。透析患者对能量和蛋白质的需求很高:每天每公斤体重需要 25-35 千卡能量和 1-1.2 克蛋白质(如果患者超重,则与 "理想 "体重有关)。蛋白质能量消耗与肾病的高发阶段有关,而营养不良则与透析存活率降低有关。应使用有效的评分方法定期评估营养状况,并解决和治疗营养不良问题。
{"title":"[Nutrition for patients on dialysis].","authors":"Martin K Kuhlmann, Susanne Fleig","doi":"10.1055/a-2199-8816","DOIUrl":"https://doi.org/10.1055/a-2199-8816","url":null,"abstract":"<p><p>Dietary recommendations for patients on dialysis are changing as our understanding of enteral microbiotal metabolism and bioavailability of nutrients from food improves.A diet low in phosphate and potassium is recommended for patients on hemodialysis. However, the absolute content does not reflect bioavailability: How much phosphate or potassium is taken up depends on food source (plant vs. animal) and to which grade it is processed. While both are nearly 100% bioavailable from industrially processed foods (additives such as dipotassium-phosphate and other salts), a much lower proportion is taken up from unprocessed plant foods high in fibre (ca. 20-40%). The DIET-HD study showed no significant association between dietary potassium and serum potassium in > 8 000 dialysis patients; and those with the highest low-processed, fresh plant-food consumption have the best survival. Dietary fibre improves colon transit time and thereby lessens symptoms of constipation. A diet low in sodium improves blood pressure and volume management in dialysis patients. The energy and protein requirements on dialysis are high: 25-35 kcal and 1-1,2 g protein per kg body weight per day (in relation to \"ideal\" body weight, if patient is overweight). Protein energy wasting is associated with higher stages of kidney disease, and malnutrition is associated with worse survival on dialysis. Nutritional status should be assessed on a regular basis using validated scores, and malnutrition should be addressed and treated.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1431-1442"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Deutsche medizinische Wochenschrift (1946)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1